Drug Trial Radar · NCT00931879
Lovaza® and Microvascular Function in Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
Oct 2009
Primary completion
Jul 2012
Study completion Jul 2012
Sponsor
- Lead sponsor
- Eastern Virginia Medical SchoolAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline
- First posted
- Jul 2, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to determine the efficacy of 6 months of 4 g/day oral Lovaza® on endothelial-dependent and heat-induced vasodilation in type 2 diabetics with neuropathy and elevated triglyceride levels. Omega-3 fatty acids appear to exert beneficial effects on vascular function that are independent of the changes in serum triglycerides. The efficacy will be compared with a placebo given at the same duration. Efficacy of the drug will be evaluated after 3 and 6 months of treatment. This timeline should be adequate for evaluation of the primary neurophysiological endpoints. Previously, the investigators have demonstrated that it is feasible to pharmacologically alter nerve fiber density in as little as 18 weeks and that this correlates with subjective and objective measures of neurovascular function. The investigators are predicting an enhancement of post-ischemic hyperemia of the foot dorsum, where the dilative mechanism is primarily endothelium-dependent and a similar improvement in heat-induced hyperemia.
Conditions
- Hypertriglyceridemia
- Diabetic Neuropathy
Interventions
omega-3-ethyl estersDrug
Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (\>500 mg/dL) triglyceride (TG) levels in adult patients.
PlaceboDrug
Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Conduction Amplitude.Time frame: One year
- Measurements of Indices of Large and Small Fiber Nerve Function Including Heart Rate Variation Measures.Time frame: One year
- Measurements of Indices of Large and Small Fiber Nerve Function Using Vibration and Thermal Thresholds.Time frame: One year
- Percent Change in Measurements of Indices of Large and Small Fiber Nerve Function Including Vibration ThresholdsTime frame: One year
- Measurements of Indices of Large and Small Fiber Nerve Function Including Markers of Inflammation and Oxidative Stress.Time frame: One year
- Efficacy Measures Are Nerve Conduction Studies; Specifically, Increases in Conduction Velocity.Time frame: One Year
- Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in Latency.Time frame: One Year
- Efficacy Measures Are Nerve Conduction Studies, Specifically Changes in F-wave ConductionTime frame: One Year
- Efficacy Measures Examining Increased Vascular Response to Ischemic Block and to Local Warming at the Dorsum of the Foot.Time frame: One Year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Strelitz Diabetes Center
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.